

## **Product datasheet for TL314481V**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **Biglycan (BGN) Human shRNA Lentiviral Particle (Locus ID 633)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** Biglycan (BGN) Human shRNA Lentiviral Particle (Locus ID 633)

Locus ID: 633

Synonyms: DSPG1; MRLS; PG-S1; PGI; SEMDX; SLRR1A

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** BGN - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001711, NM 001711.1, NM 001711.2, NM 001711.3, NM 001711.4, NM 001711.5,

BC002416, BC004244

UniProt ID: P21810

**Summary:** This gene encodes a member of the small leucine-rich proteoglycan (SLRP) family of proteins.

The encoded preproprotein is proteolytically processed to generate the mature protein, which plays a role in bone growth, muscle development and regeneration, and collagen fibril assembly in multiple tissues. This protein may also regulate inflammation and innate immunity. Additionally, the encoded protein may contribute to atherosclerosis and aortic valve stenosis in human patients. This gene and the related gene decorin are thought to be

the result of a gene duplication. [provided by RefSeq, Nov 2015]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





#### Biglycan (BGN) Human shRNA Lentiviral Particle (Locus ID 633) - TL314481V

# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).